Genomics

Dataset Information

0

Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma [CRISPR screen]

ABSTRACT: Investigation of epigenetic regulators that module hypomethylating agent response in T-cell lymphoma.

ORGANISM(S): synthetic construct

PROVIDER: GSE188569 | GEO | 2022/04/23

REPOSITORIES: GEO

Json Xml

Similar Datasets

Unknown Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma [RNA-seq]
2022-04-23 | GSE188570 | GEO
Unknown Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma
2022-04-23 | GSE188571 | GEO
Unknown Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin.
| S-EPMC5528722 | biostudies-literature
Genomics Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma [CRISPR screen]
| PRJNA779436 | ENA
Genomics Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma
| PRJNA779431 | ENA
Genomics Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma [RNA-seq]
| PRJNA779435 | ENA
Unknown Integrative Epigenetic Analysis Reveals Therapeutic Targets to the DNA Methyltransferase Inhibitor Guadecitabine (SGI-110) in Hepatocellular Carcinoma.
| S-EPMC6173644 | biostudies-literature
Unknown Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI-110) in Myeloid Malignancies.
| S-EPMC5658282 | biostudies-literature
Unknown Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma.
| S-EPMC5094635 | biostudies-literature
Unknown SGI-110: DNA Methyltransferase Inhibitor Oncolytic.
| S-EPMC4503259 | biostudies-literature